Floatz logo

102 assets in Soft Tissue Sarcoma

Therapeutic assets addressing Soft Tissue Sarcoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Palbociclib
Soft Tissue Sarcoma
Brown UniversityP2BB (69)
Nivestim
Soft Tissue Sarcoma
University of California, IrvineP3BB (68)
Cyclophosphamide
Soft Tissue Sarcoma
St. Jude Children's Research HospitalP2BB (67)
Adriamycin
Soft Tissue Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P3BB (66)
Dacarbazine
Soft Tissue Sarcoma
Institut BergoniéP3BB (66)
Irinotecan
Soft Tissue Sarcoma
GI Innovation, Inc.P1/2BB (65)
Olaparib
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP2BB (64)
Tislelizumab
Soft Tissue Sarcoma
Gustave Roussy, Cancer Campus, Grand ParisP3BB (64)
Oxaliplatin
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP2B (63)
Tazemetostat
Soft Tissue Sarcoma
Institut BergoniéP2B (62)
Fludarabine
Soft Tissue Sarcoma
Medigene AGP2B (60)
Isocyclophosphamide
Soft Tissue Sarcoma
Institut BergoniéP3B (60)
Selpercatinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2B (60)
Vemurafenib
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP2B (59)
Nivolumab
Soft Tissue Sarcoma
Instituto do Cancer do Estado de São PauloP2B (58)
Regorafenib
Soft Tissue Sarcoma
Translational Research in OncologyP2B (58)
Capecitabine
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP1/2B (57)
Cis-Diamminedichloroplatinum Ii
Soft Tissue Sarcoma
Roswell Park Cancer InstituteP1/2B (57)
Lifileucel
Soft Tissue Sarcoma
Iovance Biotherapeutics, Inc.P2B (57)
PI3K/MTOR INHIBITOR LY3023414
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2B (57)
Vismodegib
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP1/2B (57)
Carboplatin
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP1/2CCC (55)
Atezolizumab
Soft Tissue Sarcoma
OHSU Knight Cancer InstituteP1/2CCC (54)
Eribulin
Soft Tissue Sarcoma
GI Innovation, Inc.P1/2CCC (54)
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Adapt-001
Soft Tissue Sarcoma
EpicentRx, Inc.P2CCC (53)
bi 907828
Soft Tissue Sarcoma
Institut BergoniéP2CCC (53)
Cabozantinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Carbon Nanoparticle-Loaded Iron
Soft Tissue Sarcoma
Sichuan Enray Pharmaceutical Sciences CompanyP2CCC (53)
Dostarlimab
Soft Tissue Sarcoma
UNICANCERP2CCC (53)
Ensartinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Ezabenlimab
Soft Tissue Sarcoma
Institut BergoniéP2CCC (53)
Ipilimumab
Soft Tissue Sarcoma
M.D. Anderson Cancer CenterP2CCC (53)
Ivosidenib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Larotrectinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Pemigatinib
Soft Tissue Sarcoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2CCC (53)
Penpulimab
Soft Tissue Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2CCC (53)
Selumetinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
tqb2916
Soft Tissue Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2CCC (53)
Ulixertinib
Soft Tissue Sarcoma
National Cancer Institute (NCI)P2CCC (53)
Surufatinib
Soft Tissue Sarcoma
HutchmedP1/2CCC (52)
Capmatinib
Soft Tissue Sarcoma
Cancer Research UKP2/3CCC (50)
Mesna
Soft Tissue Sarcoma
St. Jude Children's Research HospitalP1/2CCC (50)
Pembrolizumab
Soft Tissue Sarcoma
GI Innovation, Inc.P1/2CCC (50)
Adenovirus-Transfected Dendritic Cells
Soft Tissue Sarcoma
Affiliated Hospital to Academy of Military Medical SciencesP1/2CCC (48)
cd146/her2 car-t cells
Soft Tissue Sarcoma
Essen BiotechP1/2CCC (48)
Ecubectedin
Soft Tissue Sarcoma
Grupo Espanol de Investigacion en SarcomasP1/2CCC (48)
Hbi 0201-Eso Tcrt
Soft Tissue Sarcoma
Hadassah Medical OrganizationP1/2CCC (48)
Onivyde
Soft Tissue Sarcoma
St. Jude Children's Research HospitalP1/2CCC (48)
Showing 1 to 50 of 102 assets
PreviousPage 1 of 3Next